[go: up one dir, main page]

RU2342130C2 - Применение агониста рецептора, активируемого пероксисомным пролифератором, для увеличения концентрации сывороточной глюкозы у жвачного животного - Google Patents

Применение агониста рецептора, активируемого пероксисомным пролифератором, для увеличения концентрации сывороточной глюкозы у жвачного животного Download PDF

Info

Publication number
RU2342130C2
RU2342130C2 RU2006140689/13A RU2006140689A RU2342130C2 RU 2342130 C2 RU2342130 C2 RU 2342130C2 RU 2006140689/13 A RU2006140689/13 A RU 2006140689/13A RU 2006140689 A RU2006140689 A RU 2006140689A RU 2342130 C2 RU2342130 C2 RU 2342130C2
Authority
RU
Russia
Prior art keywords
ruminant
use according
concentration
serum glucose
methyl
Prior art date
Application number
RU2006140689/13A
Other languages
English (en)
Russian (ru)
Other versions
RU2006140689A (ru
Inventor
Леопольд Франц ГЕТЦЕ (GB)
Леопольд Франц ГЕТЦЕ
Маркус Юджин мл. КЕРЛИ (GB)
Маркус Юджин Мл. КЕРЛИ
Энтони Пол РИКЕТТС (US)
Энтони Пол РИКЕТТС
Патрик Карл ТАУБЕ (US)
Патрик Карл ТАУБЕ
Original Assignee
Пфайзер Продактс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пфайзер Продактс Инк. filed Critical Пфайзер Продактс Инк.
Publication of RU2006140689A publication Critical patent/RU2006140689A/ru
Application granted granted Critical
Publication of RU2342130C2 publication Critical patent/RU2342130C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/111—Aromatic compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/10—Feeding-stuffs specially adapted for particular animals for ruminants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Animal Husbandry (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Birds (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Fodder In General (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Feed For Specific Animals (AREA)
RU2006140689/13A 2004-05-25 2005-05-13 Применение агониста рецептора, активируемого пероксисомным пролифератором, для увеличения концентрации сывороточной глюкозы у жвачного животного RU2342130C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57413604P 2004-05-25 2004-05-25
US60/574,136 2004-05-25

Publications (2)

Publication Number Publication Date
RU2006140689A RU2006140689A (ru) 2008-06-27
RU2342130C2 true RU2342130C2 (ru) 2008-12-27

Family

ID=35207497

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2006140689/13A RU2342130C2 (ru) 2004-05-25 2005-05-13 Применение агониста рецептора, активируемого пероксисомным пролифератором, для увеличения концентрации сывороточной глюкозы у жвачного животного

Country Status (13)

Country Link
US (1) US20070232647A1 (fr)
EP (1) EP1765320A2 (fr)
JP (1) JP2008500328A (fr)
CN (1) CN101123956A (fr)
AU (1) AU2005247172A1 (fr)
BR (1) BRPI0511613A (fr)
CA (1) CA2568009A1 (fr)
IL (1) IL178984A0 (fr)
MX (1) MXPA06013674A (fr)
NO (1) NO20065063L (fr)
RU (1) RU2342130C2 (fr)
WO (1) WO2005115369A2 (fr)
ZA (1) ZA200609104B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005247164B2 (en) * 2004-05-25 2008-11-27 Pfizer Products Inc. Specific PPAR agonists for treating negative energy balance
UA107938C2 (en) * 2009-08-12 2015-03-10 Syngenta Participations Ag Heterocycles with microbicidal properties
WO2012009542A2 (fr) * 2010-07-14 2012-01-19 Kansas State University Research Foundation Procédés de soulagement de la douleur chronique et d'amélioration de la performance du bétail subissant un écornage ou une castration
JP6864627B2 (ja) * 2015-10-08 2021-04-28 ニッソーファイン株式会社 飼料組成物
US10799519B2 (en) 2017-05-24 2020-10-13 Rupca Llc Reduced pressure maillard synthesis of carbohydrate energy supplement for ruminant livestock
EP3590354A1 (fr) * 2018-07-02 2020-01-08 PerformaNat GmbH Additif alimentaire contenant un modulateur de trp
EP3817573A1 (fr) * 2018-07-02 2021-05-12 PerformaNat GmbH Additif alimentaire comprenant un modulateur de trp
US20210353672A1 (en) * 2018-10-23 2021-11-18 D.I.T. Technologies Ltd. Compositions for administration to ruminant animals
US11389418B2 (en) 2018-12-20 2022-07-19 One Idea LLC Protection of polyunsaturated fatty acids from ruminal degradation
CN113040291A (zh) * 2021-04-07 2021-06-29 华东师范大学 PPARγ激活剂在提高水生动物抵抗环境应激能力中的应用
CN116162056A (zh) * 2021-11-24 2023-05-26 上海医药工业研究院 β-catenin/BCL9蛋白-蛋白相互作用的小分子抑制剂及其应用
WO2024145931A1 (fr) * 2023-01-06 2024-07-11 上海医药工业研究院有限公司 INHIBITEUR À PETITES MOLÉCULES POUR L'INTERACTION PROTÉINE-PROTÉINE β-CATÉNINE/BCL9 ET UTILISATION ASSOCIÉE

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2191007C2 (ru) * 1996-05-24 2002-10-20 Лиганд Фармасьютикалз Инкорпорейтед Способ лечения иhcд агонистами rxr
EP0998853B1 (fr) * 1998-11-06 2003-09-10 Rehuraisio OY Aliment pour animaux et procédé de préparation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6875780B2 (en) * 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
AU2003276596B8 (en) * 2002-11-26 2009-03-05 Pfizer Products Inc. Piperidine compounds useful as PPAR activators
GB0314624D0 (en) * 2003-06-23 2003-07-30 Advanced Bionutrition Europ Lt Inflammatory disease treatment
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
AU2005247164B2 (en) * 2004-05-25 2008-11-27 Pfizer Products Inc. Specific PPAR agonists for treating negative energy balance

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2191007C2 (ru) * 1996-05-24 2002-10-20 Лиганд Фармасьютикалз Инкорпорейтед Способ лечения иhcд агонистами rxr
EP0998853B1 (fr) * 1998-11-06 2003-09-10 Rehuraisio OY Aliment pour animaux et procédé de préparation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LOHRKE В et al., The transcription factor peroxisome proliferator activated receptor gamma (PPAR gamma) as a potential mediator of associations between metabolic and reproductive disorders, ARCHIV FUER TIERZUCHT, 1999, 42 (SONDERHEFT), 138-140. *

Also Published As

Publication number Publication date
WO2005115369A2 (fr) 2005-12-08
MXPA06013674A (es) 2007-02-13
NO20065063L (no) 2006-12-01
JP2008500328A (ja) 2008-01-10
BRPI0511613A (pt) 2008-01-02
IL178984A0 (en) 2007-05-15
AU2005247172A1 (en) 2005-12-08
CA2568009A1 (fr) 2005-12-08
ZA200609104B (en) 2008-09-25
EP1765320A2 (fr) 2007-03-28
CN101123956A (zh) 2008-02-13
WO2005115369A3 (fr) 2006-11-16
US20070232647A1 (en) 2007-10-04
RU2006140689A (ru) 2008-06-27

Similar Documents

Publication Publication Date Title
RU2342130C2 (ru) Применение агониста рецептора, активируемого пероксисомным пролифератором, для увеличения концентрации сывороточной глюкозы у жвачного животного
Alvergnas et al. Claw disorders in dairy cattle: Effects on production, welfare and farm economics with possible prevention methods
Piccione et al. Changes of some haematochemical parameters in dairy cows during late gestation, post partum, lactation and dry periods
Luthersson et al. Risk factors associated with equine gastric ulceration syndrome (EGUS) in 201 horses in Denmark
Hund et al. Aspects of lameness in pasture based dairy systems
Christodoulopoulos Foot lameness in dairy goats
Viitasaari et al. The effect of ketoprofen on post-partum behaviour in sows
JP5685364B2 (ja) トリアゾール化合物による炎症性疾患の処置
Olsson et al. The influence of diet before and after calving on the food intake, production and health of primiparous cows, with special reference to sole haemorrhages
Jogal et al. Adoption of improved animal husbandry practices by dairy farmers
Kusmartono et al. Effects of grazing chicory (Cichorium intybus) and perennial ryegrass (Lolium perenne) white clover (Trifolium repens) pasture upon the growth and voluntary feed intake of red and hybrid deer during lactation and post-weaning growth
AU773696B2 (en) Animal stereotypy
Simone-Freilicher Use of isoxsuprine for treatment of clinical signs associated with presumptive atherosclerosis in a yellow-naped Amazon parrot (Amazona ochrocephala auropalliata)
Kumar et al. Fenbendazole and praziquantel resistance in Moniezia expansa in Jamunapari goat kids
NEMAT et al. An outbreak of Chorioptes bovis mange on a dairy farm in Tabriz, Iran
Sertu The Influence of Laminitis on the Economic Efficiency of Dairy Cows
Bojkovski et al. Prevalence of claw disorders in dairy farms with tie stalls
Bampidis et al. Effect of parity and calving month on milk production and quality of Greek buffalo (Bubalus bubalis)
O'Boyle Nutrition of the periparturient dairy cow
Ametaj Metabolic disorders of dairy cattle
Kalyazina et al. HEMATOLOGICAL PARAMETERS OF PIGLETS WITH ANEMIC SYNDROME IN CASE OF APPLICATION OF CONIFEROUS ENERGY SUPPLEMENT
Holzhauer Digital Dermatitis in Dairy Cattle Is Still a Serious Problem in Western Europe
Bicalho et al. Lameness in dairy cattle: a debilitating disease or a disease of debilitated cattle
Barry et al. Effects of grazing chicory (Cichorium intybus) and perennial ryegrass (Lolium perenne)/white clover (Trifolium repens) pasture upon the growth and voluntary feed intake of red and hybrid deer during lactation and post-weaning growth
Parsons et al. Sociality in pre-and post-wean beef calves

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20090514